×
About 275 results

ALLMedicine™ Essential Thrombocytosis Center

Research & Reviews  90 results

Characterization of myeloproliferative neoplasms in the paediatric and young adult popu...
https://doi.org/10.1111/bjh.18650
British Journal of Haematology; Harris Z, Kaizer H et. al.

Jan 18th, 2023 - The aim of this study was to compare the genomic features and clinical outcomes between paediatric and young adult patients (PAYA, <40 years) and older adults (OA, ≥40 years) with myeloproliferative neoplasms (MPN) to gain insight into pathogenesi...

Secondary Thrombocytosis
https://emedicine.medscape.com/article/206811-overview

Aug 10th, 2022 - Practice Essentials Platelets are acute-phase reactants; therefore, platelet counts increase in response to various stimuli, including systemic infections, inflammatory conditions, bleeding, and tumors. [1, 2, 3] This phenomenon is called reactive...

Secondary Thrombocytosis
https://emedicine.medscape.com/article/206811-print

Aug 10th, 2022 - Practice Essentials Platelets are acute-phase reactants; therefore, platelet counts increase in response to various stimuli, including systemic infections, inflammatory conditions, bleeding, and tumors.[1, 2, 3] This phenomenon is called reactive ...

Secondary Thrombocytosis
http://emedicine.medscape.com/article/206811-overview

Aug 10th, 2022 - Practice Essentials Platelets are acute-phase reactants; therefore, platelet counts increase in response to various stimuli, including systemic infections, inflammatory conditions, bleeding, and tumors. [1, 2, 3] This phenomenon is called reactive...

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202899
PloS One; Liisborg C, Skov V et. al.

Jun 17th, 2022 - Peripheral T cell CXCR3 expression has been found uniquely lower in patients having neovascular age-related macular degeneration (nAMD) than in healthy individuals. The CXCR3-axis has been shown to have angiostatic and antifibrotic properties. We ...

see more →

Clinicaltrials.gov  6 results

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT02098161

Jun 1st, 2022 - PRIMARY OBJECTIVES: I. To determine the efficacy of LCL161 as therapy for primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis (MF) and post-essential thrombocytosis (ET) MF. II. To determine the objective response which is defin...

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
https://clinicaltrials.gov/ct2/show/NCT03869476

Sep 12th, 2019 - The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia (TE) and overt myelofibrosis (or primary myelofibrosis): prefib...

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT04054245

Aug 13th, 2019 - PRIMARY OBJECTIVES: I. To determine the efficacy of LOXL2 inhibitor PAT-1251 (PAT-1251) as therapy for primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis (MF), and post-essential thrombocytosis (ET) MF. II. To determine the obj...

Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-
https://clinicaltrials.gov/ct2/show/NCT02862366

Oct 31st, 2018 - Patients with myeloproliferative neoplasms Philadelphia chromosome negative (MPNsPh1-) such as Essential thrombocytosis (ET), Polycythemia vera (PV) and Primary Myelofibrosis (PMF) have a higher risk of arterial or deep-vein thrombosis. This is re...

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
https://clinicaltrials.gov/ct2/show/NCT00586651

Oct 8th, 2015 - This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment at a dosage of 80 mg bid for 18 weeks (126 days) in patients with Polycythemia Vera (PV) who have abnormal baseline neut...

see more →

News  13 results

European Commission Grants Orphan Drug Designation to Selinexor for Myelofibrosis
https://www.onclive.com/view/european-commission-grants-orphan-drug-designation-to-selinexor-for-myelofibrosis

Nov 1st, 2022 - The European Commission (EC) has granted an orphan drug designation to selinexor (Xpovio) for the treatment of patients with myelofibrosis.1 Selinexor, a first-in-class, oral XPO1 inhibitor, previously received an orphan drug designation for th...

Bomedemstat Demonstrates Early Promise in Advanced Myelofibrosis
https://www.onclive.com/view/bomedemstat-demonstrates-early-promise-in-advanced-myelofibrosis

Jul 26th, 2022 - Single-agent bomedemstat (IMG-7289) was found to improve symptom scores, bone marrow fibrosis, spleen volumes, and anemia in patients with advanced myelofibrosis, according to findings from the phase 1/2 IMG-7289-CTP-102 trial (NCT03136185) presen...

Addressing the Challenges in Diagnosing MF
https://www.onclive.com/view/addressing-the-challenges-in-diagnosing-mf

May 18th, 2022 - Transcript: Pankit Vachhani, MD: There are a few challenges to the diagnosis of myelofibrosis worth mentioning. One is the presentation to a clinician. Many patients who have some symptoms tend to ignore those or blame it on other causes. There c...

Making a Differential Diagnosis of Polycythemia Vera
https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

May 11th, 2022 - Transcript: Pankit Vachhani, MD: Polycythemia vera is diagnosed at a median age of roughly about 60 years. In most patients, it is actually diagnosed in an incidental fashion. Someone goes to their primary care physician or some other physician f...

5 Questions... with Charles Morris, MD, VP of Worldwide Clinical Research, for Cephalon Oncology
https://www.onclive.com/view/ong_5qs_with_charles_morris

Mar 15th, 2022 - 1 Why are self-survival and self-renewing pathways such promising areas of discovery at this time for Cephalon? If we can understand the methods and the pathways by which cells are able to either prolong their survival or sustain their own prolif...

see more →

Patient Education  1 results see all →